Note: This story was updated Oct. 12, 2020, to note that semorinemab is intended to target phosphorylated and non-phosphorylated forms…
Articles by Marisa Wexler, MS
Axsome Therapeutics announced plan to soon open a Phase 3 clinical trial of AXS-05, its investigational oral treatment for…
People in Australia with Alzheimer’s disease who have finished five years of treatment with Anavex 2-73 (blarcamesine) in Phase…
A type of mouth bacteria involved in gum disease is able to infect human brain cells, new research shows. The…
Cassava Sciences‘s investigational therapy PTI-125 failed to significantly lower the levels of Alzheimer’s-relevant biomarkers present in fluid…
Taking daily low-dose aspirin does not seem to reduce the risk of dementia, cognitive decline, or Alzheimer’s disease,…
Axsome Therapeutics is planning to complete its ADVANCE-1 clinical trial, evaluating AXS-05 as a treatment for agitation in Alzheimer’s…
Biogen is acquiring from Pfizer investigational therapy PF-05251749, a small molecule being developed to treat sundowning in …
Longer sequence repeats in or near two genes may be linked to a higher risk of late-onset Alzheimer’s disease,…
A newly opened Phase 2 clinical trial will test the sensitivity of new imaging tool for plaque buildup in the…